AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges
AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker logged a loss of $22 million, or 2 cents a share, compared to earnings of $822 million, or 46 cents a share, a year earlier.
2hon MSN
Q4 2024 Management View CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with ...
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...
AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...
Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie ...
AbbVie shares surged nearly 8% Friday morning, after the company substantially raised its sales forecasts for two key drugs. While reporting fourth-quarter revenue and earnings per share above Wall ...
The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...
Says well-positioned with ex-Humira platform for 2025. Sees clear runway for growth “for at least eight years.” Expects Skyrizi and Rinvoq to ...
U.S. equities were mostly higher at midday on positive tech earnings news and a report showing December inflation came in as expected.
As its shares pop in Friday's session, pharmaceutical giant AbbVie Inc. (ABBV) posted a fourth quarter revenue beat and raised its long-term sales guidance for new drugs Skyrizi and Rinvoq by $4 ...
2hon MSN
Read about AbbVie, Novartis, ResMed and more in the latest Market Talks covering the Health Care sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback